C
Theravance Biopharma, Inc. TBPH
$20.74 $0.371.82% NASDAQ
Recommendation
Prev Close
$20.37
Volume
339,876
Avg Vol (90D)
439,216
Market Cap
$1.03B
Dividend & Yield
--
52-Week Range
$7.90 - $21.00
P/E (TTM)
36.25
EPS (TTM)
$0.56
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)
1/22/2026 - TipRanks Financial Blog
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Here's What Happened
1/20/2026 - MarketBeat
Theravance Biopharma (TBPH, $20.11) RSI Indicator left the overbought zone on January 15, 2026
1/16/2026 - Tickeron - Technical Analysis
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
1/15/2026 - Zacks Investment Research
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts
1/15/2026 - MarketBeat
Theravance Biopharma (TBPH, $20.33) RSI Indicator left the overbought zone on January 13, 2026
1/14/2026 - Tickeron - Stocks
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - What's Next?
1/13/2026 - MarketBeat
Theravance Biopharma (TBPH, $19.65) price may drop as it broke higher Bollinger Band on Jan 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Theravance Biopharma (TBPH, $19.65) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Theravance Biopharma (TBPH, $19.04) Stochastic Oscillator left the overbought zone on January 09, 2026
1/10/2026 - Tickeron - Stocks
Theravance Biopharma (TBPH, $18.88) entered Uptrend as Momentum indicator ascends above 0 level on Jan 07, 2026
1/8/2026 - Tickeron - Stocks
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
1/6/2026 - Zacks Investment Research
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session
1/5/2026 - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Stock Price Passes Above Fifty Day Moving Average - Here's Why
1/4/2026 - Ticker Report
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average - What's Next?
1/3/2026 - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen
1/3/2026 - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) & Nektar Therapeutics (NASDAQ:NKTR) Head to Head Analysis
1/2/2026 - Ticker Report
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH
12/26/2025 - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
12/24/2025 - Zacks Investment Research
Theravance Biopharma (TBPH, $18.81) Stochastic Oscillator left the overbought zone on December 22, 2025
12/23/2025 - Tickeron - Technical Analysis
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
12/22/2025 - Zacks Investment Research
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH
12/22/2025 - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Brokerages
12/21/2025 - MarketBeat
Theravance Biopharma (TBPH, $18.18) Stochastic Oscillator left the oversold zone on December 18, 2025
12/19/2025 - Tickeron - Technical Analysis
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - Slideshow
12/15/2025 - SeekingAlpha
Income Statement
Total Revenue (TTM)
$80.33M
EBITDA (TTM)
-$31.17M
EBIT (TTM)
-$32.81M
Net Income (TTM)
$29.34M
Balance Sheet
Total Assets (Q)
$415.46M
Total Debt (Q)
$44.60M
Total Liabilities (Q)
$182.78M
Book Value Per Share (Q)
$4.59
Cash Flow
Cash from Operations (TTM)
$243.70M
Cash from Investing (TTM)
-$90.19M
Cash from Financing (TTM)
-$2.12M
Net Change in Cash (TTM)
$151.40M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
1.36
7-Day Total Return
5.55%
30-Day Total Return
14.46%
60-Day Total Return
45.24%
90-Day Total Return
45.03%
Year to Date Total Return
14.27%
1-Year Total Return
121.58%
2-Year Total Return
114.70%
3-Year Total Return
90.28%
5-Year Total Return
14.40%
52-week Low
Apr 07, 2025 - $7.90
52-week High
Jan 20, 2026 - $21.00
Valuation
Market Cap
$1.03B - Small Cap
Enterprise Value
$744.08M
Price/Sales (TTM)
13.16
Price/Book (Q)
4.44
Dividends and Shares
Shares Outstanding
51.91M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.theravance.com
Phone Number
650 808 6000
Address
901 Gateway Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed